Cure8 research brief
People with IBD and other immune conditions may develop weaker or lower‑quality antibody responses after COVID‑19 vaccination compared with healthy people, and transplant recipients showed the largest impairments. That could affect how clinicians consider booster timing or immune monitoring.
Adults with IBD, people with systemic autoimmune diseases, transplant recipients, clinicians managing immunosuppressed patients, and researchers studying vaccine responses or immune monitoring.
This observational study measured SARS‑CoV‑2 spike IgG antibody levels and antibody avidity in cohorts with IBD, other autoimmune diseases, transplant recipients, and healthy controls after multiple mRNA COVID‑19 vaccine doses. Samples were taken ~1 month and ~6 months after vaccination; validated ELISA and chaotropic‑based avidity assays were used.
Key findings reported lower antibody levels and reduced avidity in IBD and autoimmune cohorts compared with healthy controls at some time points, and markedly impaired levels and avidity in transplant recipients across doses and time points.
The paper suggests these immune patterns could inform future vaccine scheduling and immune monitoring studies in these populations.
This entry is based on the journal abstract/full text presented in Vaccines (structured content depth: abstract). The study measured antibody quantity and avidity at two post‑vaccine time points; it is observational and does not report clinical outcomes such as infection or hospitalization.
Results may vary by age, sex, vaccine manufacturer, and specific immunosuppressive treatments.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: NCI NIH HHS
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study links symptom trajectories during the first year of biologic treatment to endoscopic remission, suggesting that week 20 symptom assessment may help predict long-term outcomes for people with UC on biologics.
If you or a patient is about to start infliximab for ulcerative colitis, routine blood counts may help identify those unlikely to respond to induction therapy; a high negative predictive value suggests these markers...
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
